ANGLE Share Price (AGL)

Hi Bojo, I agree with you when you say we “cannot simply hijack our competitors and peers test because we think our own is better.”
Apologies if my post wasn’t very clear. What I was trying to say, is that rather than go head-to-head with the competition and rival liquid biopsy platforms, AN’s preferred strategy is to work with them and complement their existing services. Sounds a good plan to me.

It’s good to have some discussion back on the board and last two day’s SP rise have been very welcome.

Yes Thompi

AN does articulate the difference between Parsortix and others in the liquid biopsy space very well. However, we are brand new to the space and others are years ahead in terms of evolution, development and market penetration. Albeit with an arguably inferior test. But they are their tests. For the reasons AN points out we have every reason to see Parsortix emerge successful in time. But if you are a patient in need today, Parsortix can only help with MBC. Hopefully Ovarian will be added shortly and prostate in around a year. I would like to see these smaller tests prove clinical relevance by having more larger studies underway just like ovarian and prostate. These are our vital pipeline. Then we can get accreditation or regulatory approval.

I have seen a number of interviews & analyst presentations where AN is asked about the competition. He has always said that Parsortix can complement and enhance their services and stressed that he wants to work with them.

Sorry it’s a bit long, but this is AN’s verbatim answer to a competition related question, that the Proactive interviewer asked during the interview he gave on the day AGL received FDA approval.

“ These companies are focused on the same market area, which is liquid biopsy, but none of them are focused on recovering intact living cancer cells which are involved in spreading the disease.

These companies work with fragments of dead cells called circulating tumour DN. It only enables the investigation of DNA and actually, because the cells dead, it really gives a retrospective view. If you can get an intact cancer cell, particularly one that's in the bloodstream, spreading the disease part of the metastatic process, you've got the best possible sample for analysis and it's the closest proxy to the existing standard of care tissue biopsy. And you can look at DNA, RNA, protein expression and you can look at the actual cell. So you can look at the morphology of the cell and investigators with all number of different and laboratory techniques. So it provides a complete picture.

But the other critical thing that's different between Angle and all of the companies that you mentioned, is that they offer services. They do not have an FDA product clearance even for the CtDNA activity. They have service based clearances, which means they can offer a service from a laboratory. What we're doing is we're getting the first FDA product clearance. Which means that we can sell our Parsortix instrument and its consumables to hospitals in the United States for the intended use, and that really opens up a completely different market, because if you provide a product then everybody can use it for a whole variety of different things rather than a service.

So there's a very great distinction between us and the companies you mentioned, but equally we want to work with those companies. We're actively keen to collaborate with them, because the waste products of the CtDNA process is the blood cell components and that includes the circulating tumour cells. So with the same tube of blood from the patient, those companies if they used our products could also offer a lot wider information. So we want to work with them. It would be really complementary and we can add to their existing offerings.”

Moab,

The direct answer is look at any DNA based test. We cannot simply hijack our competitors and peers test because we think our own is better. It sounds like you are looking at this from a clinicians perspective. That being, which you would choose if you were in their shoes?

I am going for £1:10 before walk back down to 75p. How many more times will this happen before people wake up to the con?